Aimmune Therapeutics
AIMT
AIMT was delisted on the 12th of October, 2020.
125 hedge funds and large institutions have $1.07B invested in Aimmune Therapeutics in 2019 Q1 according to their latest regulatory filings, with 16 funds opening new positions, 49 increasing their positions, 34 reducing their positions, and 22 closing their positions.
44% more repeat investments, than reductions
Existing positions increased: 49 | Existing positions reduced: 34
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
3% less capital invested
Capital invested by funds: $1.1B → $1.07B (-$28.3M)
5% less funds holding
Funds holding: 132 → 125 (-7)
27% less first-time investments, than exits
New positions opened: 16 | Existing positions closed: 22
35% less call options, than puts
Call options by funds: $4.41M | Put options by funds: $6.83M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PAI
Palo Alto Investors
Palo Alto,
California
|
+$55.6M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$15M |
| 3 |
RHJA
Rice Hall James & Associates
San Diego,
California
|
+$12M |
| 4 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
+$5.25M |
| 5 |
State Street
Boston,
Massachusetts
|
+$4.34M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$14.7M |
| 2 |
Jennison Associates
New York
|
-$9.29M |
| 3 |
Bank of New York Mellon
New York
|
-$8.19M |
| 4 |
Balyasny Asset Management
Chicago,
Illinois
|
-$8.12M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$5.85M |
AIMT Hedge Fund Activity: Q1 2019 in Review
125 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Aimmune Therapeutics (AIMT) for Q1 2019, worth a combined $1.07B — down 2.6% from $1.1B a quarter earlier.
Sellers outnumbered buyers: 22 funds closed out of AIMT and 16 opened new positions — a net loss of 6 holders — while 34 trimmed existing stakes and 49 added.
The largest buyer was Palo Alto Investors, adding an estimated $55.6M. The largest seller was Point72 Asset Management, exiting entirely with an estimated $14.7M sold.
- 125 institutional investors held Aimmune Therapeutics (AIMT) as of Q1 2019, down from 132 in Q4 2018.
- Funds reported $1.07B of Aimmune Therapeutics stock for Q1 2019, down 2.6% quarter-over-quarter.
- 16 funds opened new Aimmune Therapeutics positions in Q1 2019 and 22 closed out, a net change of -6 holders.
- The largest Aimmune Therapeutics buyer in Q1 2019 was Palo Alto Investors, an estimated $55.6M added.
- The largest Aimmune Therapeutics seller in Q1 2019 was Point72 Asset Management, an estimated $14.7M sold.
Based on aggregated 13F filings for Q1 2019.